
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical is poised to benefit from a large, growing, and underpenetrated market opportunity in the global body contouring market. With its Renuvion technology addressing skin contraction and AYON supporting liposuction, the company is well-positioned to participate across a broader spectrum of body contouring procedures. The company has a strong track record of efficacy and clinical validation, with more than 100 published clinical papers supporting its technology, and a high-margin, recurring revenue business model. In addition, Apyx is transitioning to a scalable surgical aesthetics platform with the launch of AYON, which has the potential to significantly expand its addressable market and drive sustainable cash flow generation. The company also has a strong leadership team with experienced executives in the medical device industry.
Bears say
Apyx Medical is a company that offers a range of cosmetic and surgical products and technologies used in medical settings. Despite its strong patent portfolio and unique FDA-cleared helium plasma device, the company has a history of net losses and potential legal and financial risks. Additionally, its operating cash flows have been negative and its price target is $7 per share.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares